Pulmonary Hypertension: New Insights and Recent Advances

A Special Issue of Journal of Respiration (ISSN 2673-527X).

Deadline for manuscript submissions: 20 November 2026 | Viewed by 999

Editors


E-Mail Website
Guest Editor
Department of Medicine, University of Houston, Houston, TX 77840, USA
Interests: critical care; quality improvement; pulmonary hypertension; IPF; sleep medicine; sepsis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Internal Medicine Department, Aga Khan University, Nairobi, Kenya
Interests: pulmonary hypertension; congestive heart failure; myocardial infarction; hospital mortality

E-Mail Website
Guest Editor
Division of Pulmonary, Critical Care and Sleep Medicine, Baylor Scott and White, Temple, TX 76508, USA
Interests: pulmnary hypertension; CTEPH; critical care; chest infection; interstitial lung disease; AI in medicine

Special Issue Information

Dear Colleagues,

Pulmonary hypertension is a heterogeneous group of conditions leading to high morbidity and mortality. It is characterized by progressive pulmonary vascular disease and right ventricular dysfunction. There have been substantial advances in imaging technology, genetics, and cellular biology, which have helped in understanding disease mechanisms and identifying additional phenotypes and their features. These developments have helped us diagnose and manage the disease, as well as drive innovations in therapeutics. Despite this progress, there remain challenges in both diagnosis and management, as well as in long-term outcomes.

This Special Issue provides readers with comprehensive, up-to-date coverage of pulmonary hypertension while also presenting historical facts. We urge investigators and clinicians to submit comprehensive reviews, systematic reviews, and meta-analysis articles, as well as research articles, including original observational, retrospective, and prospective studies. We like to address progress in understanding pathophysiology, diagnostic management, phenotype identification, genetics, and drug development. We also like to address the current outcomes and future development, as well as present the latest guidelines.

We hope to bring together clinicians, patient advocates, regulators, scientists, and researchers on this issue to address current challenges and outcomes and improve the future outcomes of this condition.

We look forward to receiving your contributions.

Dr. Salim Surani
Dr. Mohamed Hasham Varwani
Dr. Munish Sharma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary pulmonary hypertension
  • secondary pulmonary hypertension
  • CTEPH
  • artificial intelligence
  • genetics in PH
  • latest therapy in PH

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

19 pages, 2458 KB  
Systematic Review
Pulmonary Vasodilators in COPD-Associated Pulmonary Hypertension: An Updated Meta-Analysis of Randomized Evidence
by Micah Nnabuko Okwah, Ihesiulo Alozie, Jeremiah Adepoju, Itua Abhulimen, Obinna Adolalom, Oluwasegun Oladeji, Olaitan Akinrele, Ihesiulo Chigozie, Anim Asif, Shubhendu Bajpai, Elijah Akinbi, Ayotunde Famokunwa, Jesunifemi Esebame and Ismaila Ajayi Yusuf
J. Respir. 2026, 6(3), 18; https://doi.org/10.3390/jor6030018 - 6 Aug 2026
Viewed by 305
Abstract
Background: Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD), termed COPD-associated pulmonary hypertension (COPD-PH), and is associated with worse clinical outcomes. The efficacy and safety of pulmonary vasodilators in COPD-PH remain uncertain. Methods: We performed a systematic review [...] Read more.
Background: Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD), termed COPD-associated pulmonary hypertension (COPD-PH), and is associated with worse clinical outcomes. The efficacy and safety of pulmonary vasodilators in COPD-PH remain uncertain. Methods: We performed a systematic review and meta-analysis of randomized studies evaluating pulmonary vasodilators in adults with COPD-PH. Fifteen studies were identified, with 11 contributing to quantitative analyses. Outcomes included six-minute walk distance (6MWD), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), partial pressure of arterial oxygen (PaO2), and systolic pulmonary arterial pressure (sPAP). Results: Pulmonary vasodilators significantly reduced mPAP (MD −3.88 mmHg, 95% CI −7.23 to −0.53) and PVR (SMD −0.90, 95% CI −1.70 to −0.10). However, no significant improvements were observed in 6MWD or PaO2. An exploratory composite hemodynamic score supported an overall hemodynamic benefit. Subgroup analyses suggested a more favorable profile for nitric oxide donors, whereas endothelin receptor antagonists were associated with worsened oxygenation. Conclusions: Pulmonary vasodilators improve pulmonary hemodynamics in COPD-PH but do not consistently improve exercise capacity or oxygenation. Current evidence does not support routine use outside specialized centers or clinical trials, and treatment effects appear to vary by drug class. Full article
(This article belongs to the Special Issue Pulmonary Hypertension: New Insights and Recent Advances)
Show Figures

Figure 1

Back to TopTop